ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Primordial Prevention of CVD in Young

The future of cardiovascular health depends on prevention that begins early in life. This episode reviews strategies for recognizing cardiovascular risk at an early stage

Umbrella: Cardioprotection During Treatment

Cardiovascular protection during cancer treatment is critical to help prevent complications such as heart failure. Patients should be educated on risk factors, symptom aw

No Murmur But Much Fervor: Nonobstructive HCM

Nonobstructive hypertrophic cardiomyopathy (HCM) represents one of the greatest areas of unmet need in HCM management. A key question is identifying the primary driver of

Evolocumab In Patients Without Significant Atherosclerosis: Results From VESALIUS-CV

The VESALIUS-CV trial demonstrated that the PCSK9 inhibitor evolocumab significantly reduced the risk of a first major cardiovascular event in patients with diabetes who

Why Can't We Prove Revascularization Is Better Than Medical Therapy for SIHD?

Randomized trials in stable ischemic heart disease (SIHD) show revascularization does not reduce death or myocardial infarction versus guideline-directed medical therapy,

Top Practice-Changing Advancements in Echocardiography Since ACC.25

ecent advancements in echocardiography since ACC.25 highlight a shift toward greater precision, efficiency, and consistency in cardiac imaging. Standardized echo reportin

The Case For Medically Tailored Meals

The "Food is Medicine" approach is central to cardiovascular disease (CVD) prevention because diet directly shapes key risk factors, making nutrition a powerful, modifiab

Managing Subclinical AFib Detected by Devices, Ambulatory Monitors and Wearables

The detection of subclinical, or "silent," atrial fibrillation (AFib) has increased substantially with the widespread use of implantable devices (e.g., pacemakers, defibr

Cardiorenal Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Diabetes and CVD

Is tirzepatide associated with a broader reduction in cardiorenal adverse outcomes compared with dulaglutide in patients with type 2 diabetes and cardiovascular disease (

Impact Of Ivabradine in Post-COVID POTS: The Recover-Autonomic Trial

The Recover-Autonomic Trial evaluates the impact of ivabradine on orthostatic intolerance, quality of life, and heart rate in patients with post-COVID postural orthostati

Prehospital Heparin Administration In Patients With STEMI Undergoing Primary PCI

Prehospital heparin administration in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) offers

Definitions and Treatment of Iron Deficiency in HF: Feel and Function or More?

Iron deficiency (ID) is highly prevalent in patients with heart failure (HF) and is independently associated with poorer functional status, higher hospitalization rates,

Key Take-Home Messages From the 2025 Sports Cardiology Guidelines

There is increasing emphasis on shared decision-making when evaluating sports participation for competitive athletes with cardiovascular disease, reflecting a shift towar

Insights From the CADENCE Trial

In the CADENCE proof-of-concept study, sotatercept demonstrated meaningful improvements in pulmonary vascular and cardiac hemodynamics in patients with combined pre‑ and 

A Look At The ORBITA-CTO Trial

The ORBITA-CTO trial was a multicenter, randomized, double-blinded study that enrolled 50 patients with symptomatic single-vessel chronic total occlusion (CTO) and no bys

THRIVE Food is Medicine Pilot Trial: Addressing Hypertension Through Produce Prescriptions

The American Heart Association–funded THRIVE Food is Medicine pilot trial demonstrated strong promise in addressing hypertension through produce prescriptions. Participan

Inflammation in CVD: A 2025 ACC Scientific Statement

Inflammation has emerged as a critical contributor to the pathogenesis and clinical outcomes of cardiovascular disease (CVD), with growing evidence highlighting the progn

Lower LDL-C for Longer? Defining the Optimal Timing and Intensity of Rx

Should statin therapy be routinely initiated in middle‑aged adults with at least one atherosclerotic cardiovascular disease risk factor and LDL‑C levels above 100 mg/dL? 

Keeping it Simple: Top 10 Things to Know About the 2026 Dyslipidemia Guideline

The 2026 ACC/AHA Dyslipidemia Guidelines highlight that Lp(a) confers a graded ASCVD risk, with levels around 125 nmol/L (50 mg/dL) indicating meaningful risk and ~250 nm

Heart and Liver Health: Interconnectedness of CV and Hepatic Risk

ardiac and hepatic function are closely interconnected, with deterioration in one organ often accelerating disease progression in the other. Emerging evidence, including